ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0269 • ACR Convergence 2025

    Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group

    Paula García-Escudero1, Marta López2, Berta Magallares3, Dolly Viviana Fiallo Suárez4, Diego Dios Santos5, César Antonio Egües Dubuc6, Santos Castañeda7, Alicia Garcia8, Isla Morante Bolado9, Elena María Oliver García10, Clara Garcia Belando11, Cristina Corrales12, Francisco Javier Toyos13, Judit Font-Urgelles14, Meritxell Salles Lizarzaburu15, Carolina Merino16, Irene Carrion17, Jose Angel Hernandez18, Lourdes Villalobos19, Alina-Lucica Boteanu20, Beatriz Frade Sosa21, cristiana Sieiro22, Irene Monjo Henry23, Ernesto Trallero24, Eugenia Enriquez25, Maria Rodriguez26, Elena Riera Alonso27, Marta Ibañez28, Delia Reina29, Rafael Benito Melero González30, Giuliano Boselli31, Alberto Mariano32, Ignacio Vázquez Gómez33, Jose Alberto Miranda34, Clara Moriano35, Elena Aurrecoechea36, Paloma Vela Casasempere37, Iñigo Rúa-Figueroa38 and Jaime Calvo39, 1Hospital Universitario Álava, Bilbao, Spain, 2Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 3Hospital de Sant Pau, Bareclona, 4H.U. Doctor Negrín, Gran Canarias, 5C. H. U. A Coruña, A Coruña, Spain, 6Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, 7Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 8Rheumatologist, La Laguna, Spain, 9Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, 10H.C. U. Lozano Blesa, Zaragoza, 11H.C. U. Virgen de la arrizaca, Murcia, 12HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, 13Virgen Macarena University Hospital,, Sevilla, Spain, 14Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 15Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, 16Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, 17Hospital del Mar, Barcelona, Spain, 18Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, 19Ramon y Cajal Hospital, MADRID, Spain, 20H.U. Ramón y Cajal, Madrid, Spain, 21Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 22Univrsity of Manchester, Manchester, United Kingdom, 23Hospital Universitario La Paz, Madrid, Spain, 24H. U. Vall d'Hebron, Barcelona, 25Clínica Universidad de Navarra, Madrid, Spain, 26H. Clínico San Carlos, Madrid, Spain, 27Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 28Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 29Complex Hospitalari Moisès Broggi, Barcelona, Spain, 30C. H. U. de Ourense, Ourense, 31Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, 32Virgen del Rocío University Hospital, Sevilla, Spain, 33H.U. Doctor Peset, Valencia, 34C. H. U. Lucus Augusti, Lugo, Spain, 35Hospital León, LEON, Castilla y Leon, Spain, 36H. Sierrallana, Santander, 37Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 38Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, 39Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain

    Background/Purpose: VEXAS syndrome is a rare disease caused by somatic mutations in UBA1 gene. Different mutations in this gene appear to be associated with specific…
  • Abstract Number: 0283 • ACR Convergence 2025

    The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records

    Ana Valle1, Amy Vo2, Rochelle Castillo1, Yumeko Kawano3, Leah Santacroce3, Daniel Solomon4, Katherine Liao3 and Candace Feldman3, 1Brigham and Women's Hospital, Brookline, MA, 2Harvard Medical School, Boston, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM; including dermatomyositis, polymyositis, and inclusion body myositis) are heterogenous systemic inflammatory conditions that cause significant disability and morbidity. The study…
  • Abstract Number: 0065 • ACR Convergence 2025

    Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis

    Wenxian Zhou1, Hannah Johnson2, Michael Duryee2, Ali Namvaran3, Julian Garcia2, Carlos Hunter2, Tate Johnson2, Daniel Anderson4, Kishore Bidasee2, Geoffrey Thiele2 and Ted Mikuls2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Nebraska Medical Center, Omaha, 40587964, Durham, NC

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience increased morbidity and mortality due to heart failure with preserved ejection fraction (HFpEF), a condition characterized by diastolic…
  • Abstract Number: 0085 • ACR Convergence 2025

    Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease

    Kensuke Suga1, Amara Seng2, Changfu Yao3, Tanyalak Parimon3, Youn Jung Choi2, Justyna Fert-Bober4, Barry Stripp3, Jon Giles5, Peter Chen3 and Nunzio Bottini6, 1Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, 2Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 4Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 5Cedars Sinai Medical Center, Los Angeles, CA, 6Cedars Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
  • Abstract Number: 0325 • ACR Convergence 2025

    Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)

    C. Kent Kwoh1, Amanda Nelson2, Rongrong Tang3, Edward J. Bedrick3, Yong Ge1, Yvonne Golightly4, Zong-Ming Li3, Jean Liew5, Xiaoxiao Sun1, Jeffrey Duryea6 and Tuhina Neogi5, 1The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3The University of Arizona Arthritis Center, University of Arizona, Tucson, 4University of Nebraska Medical Center, Omaha, NE, 5Boston University School of Medicine, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…
  • Abstract Number: 0317 • ACR Convergence 2025

    “No matter how great my doctor is, he hasn’t had a knee replacement, he doesn’t understand all that pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement

    Cara Murphy1, Sarah Young2, Vanessa Madrigal3, Noelia Hernandez4, Daniel Garcia5, Yuliana Dominguez Paez6, Monika Safford3, Iris Navarro-Millan7 and Mackenzie Brown8, 1HSS, New York, NY, 2Weill Cornell Medicine, Johnson City, NY, 3Weill Cornell Medicine, New York, 4Weill Cornell Medicine, New York, NY, 5Weill Cornell, Brooklyn, NY, 6Albert Einstein College of Medicine, The Bronx, NY, 7Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, 8Weill Cornell Medicine, Brooklyn, NY

    Background/Purpose: Moving Well was a pre-habilitation peer coach intervention aimed at reducing levels of anxiety, depression, and pain among individuals undergoing total knee replacement (TKR)1.…
  • Abstract Number: 0232 • ACR Convergence 2025

    Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience

    Zeinab Saleh1, Michelle Kahlenberg2, Wendy Marder1 and Emily Somers1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Measuring hydroxychloroquine (HCQ) blood levels in patients with systemic lupus erythematosus (SLE) can assess medication adherence and determine whether concentrations fall within the therapeutic…
  • Abstract Number: 0220 • ACR Convergence 2025

    National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration

    Alissa Becerril1, Jing Li2, Cherish Wilson3, Gary Tarasovsky4, Abimbola Fadairo-Azinge5, Mary Whooley4 and gabriela Schmajuk6, 1UCSF, san francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA, 4SFVA, San Francisco, 5UCSF, San Francisco, 6University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Background/Purpose: Allopurinol can cause life-threatening severe cutaneous adverse reactions, especially in patients who carry the HLA-B58:01 allele. Because this allele is more common among Southeast…
  • Abstract Number: 0286 • ACR Convergence 2025

    Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients

    Connor Buechler1 and David Pearson2, 1University of Minnesota, Mendota Heights, MN, 2Department of Dermatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…
  • Abstract Number: 0294 • ACR Convergence 2025

    Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.

    Jocelyn Hui Ching Chow1, Nikola Wilk2, Ian Smith3, Ronald A. Booth4, Nancy Maltez2, Catherine Ivory2 and Jodi Warman-Chardon5, 1Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, 2Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, 3Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, 4Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, 5Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada

    Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that often present with multisystem involvement. Autoantibodies such as myositis-specific…
  • Abstract Number: 0293 • ACR Convergence 2025

    Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis

    Jackie Weiss1, Miriam Mende2, EunByul Cho3, Guo Shen3, Dmitry Karayev3, Allan L. Metzger3, Robert I. Morris3, Sabine L. Kramp2, Cornelia Dähnrich2 and Wolfgang Schlumberger2, 1EUROIMMUN US, Mountain Lakes, NJ, 2Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany, 3RDL Reference Laboratory Inc., Los Angeles, CA

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is an autoimmune disease manifesting with muscle degeneration, inflammatory infiltrates and inclusion vacuoles. Diagnosis of sIBM is hampered by…
  • Abstract Number: 0304 • ACR Convergence 2025

    Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region

    Takahisa Gono1, Vidya Limaye2, Latika Gupta3, Vikas Agarwal4, Ho So5, JASMIN RAJA6, Warren Weng Seng Fong7, Suparaporn Wangkaew8, Andrea Low9, Akihiro Murakami10, Kimiko Hasegawa10, Takuya Isayama11 and Masataka Kuwana1, 1Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Royal Adelaide Hospital, Adelaide, South Australia, Australia, 3School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 6University Malaya, Subang Jaya, Malaysia, 7Singapore General Hospital, Singapore, 8Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, 9Singapore General Hospital, Singapore, Singapore, 10Medical & Biological Laboratories co., ltd., Tokyo, 11Medical & Biological Laboratories co., ltd., Tokyo, Japan

    Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
  • Abstract Number: 0329 • ACR Convergence 2025

    Machine Learning-Based Model to Predict Rapid Structural Progression in Knee Osteoarthritis

    Maria Fernanda Gonzalez Hernandez1, Ignacio rego Pérez2, Isabel Rodríguez Valle3, Jorge Vázquez García4, Vanesa Balboa5, Sara Relaño Fernández4, María C. de Andrés6, Lucía Lourido7, Valentina Calamia7, Rocio Paz González4, Patricia Quaranta7, Patricia Fernández-Puente4, Nicola Veronese8, Cristina Ruiz-Romero9, Natividad Oreiro10 and francisco J Blanco11, 1Instituto de Investigacion Biomedica de A Coruna (INIBIC), A coruña, Galicia, Spain, 2Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, 3Instituto de Investigacion Biomedica de A Coruna (INIBIC), Coruña, Galicia, Spain, 4Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruña, Spain, 5Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, 6Instituto de Investigación Biomédica de A Coruña (INIBIC), Grupo de Investigación de Reumatología (GIR), A Coruña, Spain, 7Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruna, Spain, 8Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, palermo, Italy, 9Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, 10CHUAC, La Coruna, Spain, 11INIBIC-University of A Coruña, A Coruña, Galicia, Spain

    Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disorder, characterized by structural cartilage and bone damage that often causes pain and disability. However, the…
  • Abstract Number: 0211 • ACR Convergence 2025

    Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration

    Alexandra Do1, Lisa Matsumoto1, Cherish Wilson2, Gary Tarasovsky3, gabriela Schmajuk4 and Jennifer Barton5, 1Oregon Health and Science University, Portland, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, 4University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 5VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
  • Abstract Number: 0218 • ACR Convergence 2025

    Creating an EHR Lupus Outreach Workbench to Address Care Gaps

    Ross Gilbert1, Starla Blanks2, Joy Buie3, Mary Cronin4, Jake Decker5, Laura Dickmann6, Cristina Drenkard7, Sancia Ferguson8, Shivani Garg9, David Gazeley5, Andrea Gilmore-Bykovskyi10, Gale Johnson11, Patti Katz12, Tristan Lazewski13, S. Sam Lim14, Jenna McGoldrick15, Katrina Phelps10, Edmond Ramly16, Rosalind Ramsey-Goldman17, Ann Rosenthal18, Dawn Thomas-Semanko19, Sarah Stoltz13, Patricia Tellez-giron20, Amannda Weber21, Andrea Wipperfurth13 and Christie Bartels10, 1Johns Hopkins University, Baltimore, MD, 2American College of Rheumatology, Atlanta, GA, 3Lupus Foundation of America, Washington, DC, 4retired, Fox Point, WI, 5Medical College of Wisconsin, Milwaukee, WI, 6Froedtert Health, Waukesha, WI, 7Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, 8University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, 9University of Madison, School of Medicine and Public Health, Madison, WI, 10University of Wisconsin School of Medicine and Public Health, Madison, WI, 11Wisconsin Department of Health Services, Madison, WI, 12UCSF, San Rafael, CA, 13UW Health, Madison, WI, 14Emory University School of Medicine, Atlanta, GA, 15SSM Health, Madison, WI, 16Indiana University - Bloomington, Bloomington, IN, 17Northwestern University Feinberg School of Medicine, Chicago, IL, 18Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, 19WI Chapter - LFA, Milwaukee, WI, 20University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 21University of Wisconsin (UW), UW Health, Madison, WI

    Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology